Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan Sells 2,771 Shares

Enfusion, Inc. (NYSE:ENFN) CEO Oleg Movchan sold 2,771 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $10.13, for a total transaction of $28,070.23. Following the completion of the transaction, the chief executive officer now owns 526,702 shares in the company, valued at $5,335,491.26. This trade represents a 0.52 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Enfusion Trading Down 3.1 %

ENFN opened at $9.97 on Friday. The firm has a market capitalization of $1.28 billion, a PE ratio of 249.31, a P/E/G ratio of 3.98 and a beta of 0.95. Enfusion, Inc. has a 12-month low of $7.52 and a 12-month high of $11.38. The firm has a 50 day moving average of $10.11 and a two-hundred day moving average of $9.19.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ENFN. Stifel Nicolaus raised their target price on shares of Enfusion from $11.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, December 18th. Piper Sandler upped their price objective on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd. Three equities research analysts have rated the stock with a sell rating, one has given a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $10.25.

Institutional Trading of Enfusion

Large investors have recently made changes to their positions in the company. Arizona State Retirement System acquired a new stake in shares of Enfusion during the 2nd quarter worth approximately $86,000. Harbor Capital Advisors Inc. boosted its position in Enfusion by 12.4% in the 3rd quarter. Harbor Capital Advisors Inc. now owns 11,887 shares of the company’s stock valued at $113,000 after buying an additional 1,315 shares during the period. Belvedere Trading LLC acquired a new stake in Enfusion in the 3rd quarter valued at about $114,000. Paloma Partners Management Co acquired a new position in Enfusion during the 3rd quarter worth approximately $157,000. Finally, The Manufacturers Life Insurance Company raised its stake in Enfusion by 27.7% in the second quarter. The Manufacturers Life Insurance Company now owns 19,562 shares of the company’s stock valued at $167,000 after buying an additional 4,239 shares in the last quarter. 81.05% of the stock is currently owned by hedge funds and other institutional investors.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.